The global acute myeloid leukemia (AML) market size is estimated to be valued at USD 1.74 Billion in 2025. It can reach a valuation of USD 2.92 Billion by 2032, by exhibiting a CAGR of 7.7% throughout the forecast period (2025-2032).
Acute myeloid leukemia is a cancer found in the bone marrow and affects the production of blood cells. The market for AML is driven by the vulnerability of the elderly to the disease, coupled with leaps in personalized medicine and targeted therapies, which can drive the market growth. In addition, the rising number of refractory patients with AML offers a good market opportunity for novel drugs.
However, the high prices of drugs and stringent product approvals can hinder the market growth.
Key Market Insights
The acute myeloid leukemia (AML) market is likely to be shaped by recent advances in AML therapeutics.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/acute-myeloid-leukemia-aml-market
Acute Myeloid Leukemia (AML) Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 1.74 Billion |
|
Estimated Value by 2032 |
USD 2.92 Billion |
|
Growth Rate |
7.7% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The innovative nature of drugs for treating AML has led to various biotechnology startups to operate in stealth mode. This enabled them to work in secrecy on their projects without revealing information to competitors or the public. This has been a consistent trend in the acute myeloid leukemia (AML) market due to its competitive nature and the need to protect intellectual property portfolio of drugs and therapies. A perfect example would is Edgewood Oncology, which moved out of stealth mode on March 25, 2024. It revealed its early-stage research for BTX-A51, a treatment option for AML, after receiving a financial backing of USD 20 million from Alta Partners to expedite its research.
The rise of menin inhibitors as a new form of targeted therapy for certain leukemias can drive their development in the market. A strong pipeline of genetically targeted therapies, combined with the need for immediate treatments for hematologic malignancies, can drive the market growth. This comes in line with the recent announcement of USD 80 million in capital received by Charm Therapeutics, from NVIDIA, on September 02, 2025. An increase in R&D investments and partnerships between biotech startups and pharmaceutical companies can augur favorably for the market over the forecast period.
Market Opportunity: FLT3 Inhibitors in Combination Therapies
The high success rate displayed by FLT3 inhibitors can drive their use in induction chemotherapy sessions. The development of alternatives to midostaurin, a FLT3 inhibitor developed by Novartis, due to its gastrointestinal toxicity, will provide relief to AML patients. The success of these therapies can be tested using the plasma inhibitory activity assay. Lastly, the ongoing clinical trials of the combination therapy of Venetoclax plus FLT3 inhibitors may lead to further opportunities for drug development.
Market Challenge: High Toxicity of Current Regimens
The high toxicity associated with current regimens, especially cytarabine combination therapies, can negatively affect the market growth. Severe side-effects such as cardiotoxicity and myelosuppression can be unsuitable for the elderly or frail patients. The development of safe and less toxic alternatives for patients receiving intense chemotherapy can be beneficial for the market.
Analyst’s View
Recent Developments
AbbVie introduced VENCLEXTA (Venetoclax) on April 21, 2025, for the treatment of AML in India. The drug offers hope to patients who are unable to undergo intensive chemotherapy.
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :